In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
Peptides
- Latest Posts
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
In Depth 22 Nov 2023
Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment
Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […]
Podcast 11 Aug 2023
Beyond Biotech podcast 58 – Pepteins
To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a […]
News and Trends 7 Jul 2023
Swedish researchers look to peptides to destroy viruses
A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 1 Jun 2023
Swiss researchers develop new class of antibiotics to fight resistant bacteria
Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […]
News and Trends 17 May 2023
Diagnosing inflammatory diseases with synthetic peptides
Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […]
In Depth 5 Apr 2023
Antimicrobial peptides: a promising class to tackle antimicrobial resistance
The discovery of penicillin in 1928 by Alexander Fleming was a momentous moment in the world of healthcare, eventually leading to the development of antibiotic drugs that allowed physicians to treat illnesses and infections that were once severe and life-threatening. But our reliance on antibiotics has now led to an emerging global health problem in […]
News and Trends 31 Mar 2023
Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China
Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]
News and Trends 9 Mar 2023
Iktos raises €15.5M to expand AI drug discovery technologies
Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […]
News and Trends 23 Feb 2023
Korean researchers develop antimicrobial peptides discovery tool
Antimicrobial peptides (AMPs) are a promising new weapon for combating the growing antimicrobial resistance (AMR) of bacteria and other harmful microorganisms. Now, researchers from the Gwangju Institute of Science and Technology (GIST) in South Korea have developed a new, easy-to-interpret AI-powered AMP prediction model. The tool, named AMP-BERT, can capture the functional and structural properties […]
ADVERTISEMENT